Onconova Therapeutics,Inc. (NASDAQ:ONTX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07. Submission of Matters to a Vote of Security Holders.
On May17, 2017, Onconova Therapeutics,Inc. (the Company) held its
2017 Annual Meeting of Stockholders. At the Annual Meeting, the
Companys stockholders voted on the following proposals:
1. To elect the eight nominees named in the Companys proxy
statement to serve for a one-year term as a director of the
Company expiring at the Companys 2018 Annual Meeting of
Stockholders and, in each case, until a successor is elected and
qualified. Each nominee for director was elected by a vote of the
stockholders as follows:
|
Name |
|
For |
|
Withheld |
|
BrokerNon-Votes |
|
Henry S. Bienen |
2,607,529 |
440,900 |
2,158,884 |
|||
|
Jerome E. Groopman |
2,606,369 |
442,060 |
2,158,884 |
|||
|
Michael B. Hoffman |
2,607,741 |
440,688 |
2,158,884 |
|||
|
Ramesh Kumar |
2,607,661 |
440,768 |
2,158,884 |
|||
|
James J. Marino |
2,606,359 |
442,070 |
2,158,884 |
|||
|
Viren Mehta |
2,607,641 |
440,788 |
2,158,884 |
|||
|
E. Premkumar Reddy |
2,607,459 |
440,970 |
2,158,884 |
|||
|
Jack E. Stover |
2,606,359 |
442,070 |
2,158,884 |
2.To ratify the selection of Ernst Young LLP as the Companys
independent registered public accounting firm for the fiscal year
ended December31, 2017. The proposal was approved by a vote of
the stockholders as follows:
|
For |
|
Against |
|
Abstain |
|
BrokerNon-Votes |
|
4,782,359 |
13,127 |
411,827 |
|
About Onconova Therapeutics, Inc. (NASDAQ:ONTX)
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company’s lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib. Onconova Therapeutics, Inc. (NASDAQ:ONTX) Recent Trading Information
Onconova Therapeutics, Inc. (NASDAQ:ONTX) closed its last trading session down -0.05 at 2.00 with 95,313 shares trading hands.